Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

Identification of a candidate gene panel for the early diagnosis of prostate cancer.

Leyten GH Giseleleyten Hotmail Com, Hessels D, Smit F, Jannink S, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Schalken JA.

Clin Cancer Res. 2015 Mar 18. pii: clincanres.3334.2014. [Epub ahead of print]

PMID:
25788493
2.

Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer.

Arends TJ, Lammers RJ, Falke J, van der Heijden AG, Rustighini I, Pozzi R, Ravic M, Eisenhardt A, Vergunst H, Witjes JA.

Clin Genitourin Cancer. 2014 Dec 31. pii: S1558-7673(14)00284-5. doi: 10.1016/j.clgc.2014.12.010. [Epub ahead of print]

PMID:
25660383
3.

Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.

Hoeks CM, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Roobol MJ, Bul M, Hambrock T, Witjes JA, Fütterer JJ, Hulsbergen-van de Kaa CA, Barentsz JO.

Invest Radiol. 2014 Mar;49(3):165-72. doi: 10.1097/RLI.0000000000000008.

PMID:
24220253
4.

Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection.

Somford DM, Vreuls W, Jansen TS, van Basten JP, Vergunst H.

World J Urol. 2014 Apr;32(2):461-7. doi: 10.1007/s00345-013-1130-3. Epub 2013 Jul 20.

PMID:
23873356
5.

Alpha emitter radium-223 and survival in metastatic prostate cancer.

Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators.

N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.

6.

The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.

Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, van Oort IM, Vergunst H, Kiemeney LA, Barentsz JO, Witjes JA.

J Urol. 2013 Nov;190(5):1728-34. doi: 10.1016/j.juro.2013.05.021. Epub 2013 May 13.

PMID:
23680307
7.

Quality of life after prostate cancer treatments in patients comparable at baseline.

van Tol-Geerdink JJ, Leer JW, van Oort IM, van Lin EJ, Weijerman PC, Vergunst H, Witjes JA, Stalmeier PF.

Br J Cancer. 2013 May 14;108(9):1784-9. doi: 10.1038/bjc.2013.181. Epub 2013 Apr 23.

8.

MR imaging-guided focal cryoablation in patients with recurrent prostate cancer.

Bomers JG, Yakar D, Overduin CG, Sedelaar JP, Vergunst H, Barentsz JO, de Lange F, Fütterer JJ.

Radiology. 2013 Aug;268(2):451-60. doi: 10.1148/radiol.13121291. Epub 2013 Mar 22.

PMID:
23525206
9.

Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer.

Somford DM, Hoeks CM, Hulsbergen-van de Kaa CA, Hambrock T, Fütterer JJ, Witjes JA, Bangma CH, Vergunst H, Smits GA, Oddens JR, van Oort IM, Barentsz JO; MR-PRIAS Collaboration Group.

Invest Radiol. 2013 Mar;48(3):152-7. doi: 10.1097/RLI.0b013e31827b711e.

PMID:
23328910
10.

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.

Falke J, Lammers RJ, Arentsen HC, Ravic M, Pozzi R, Cornel EB, Vergunst H, de Reijke TM, Witjes JA.

J Urol. 2013 Jun;189(6):2077-82. doi: 10.1016/j.juro.2012.11.150. Epub 2012 Nov 30.

PMID:
23206424
11.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
12.

Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.

Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2013 Apr;63(4):597-603. doi: 10.1016/j.eururo.2012.11.005. Epub 2012 Nov 12.

PMID:
23159452
13.

Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review.

Peters M, Moman MR, van der Poel HG, Vergunst H, de Jong IJ, Vijverberg PL, Battermann JJ, Horenblas S, van Vulpen M.

World J Urol. 2013 Apr;31(2):403-9. doi: 10.1007/s00345-012-0928-8. Epub 2012 Aug 18. Review.

PMID:
22903773
14.

Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.

van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF.

BJU Int. 2013 Apr;111(4):564-73. doi: 10.1111/j.1464-410X.2012.11402.x. Epub 2012 Aug 10.

PMID:
22882966
15.

Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, Vergunst H, Sedelaar JP, Fütterer JJ, Barentsz JO.

Eur Urol. 2012 Nov;62(5):902-9. doi: 10.1016/j.eururo.2012.01.047. Epub 2012 Feb 1.

PMID:
22325447
16.

Prognostic factors for survival in patients with recurrence of muscle invasive bladder cancer after treatment with curative intent.

Ploeg M, Kums AC, Aben KK, van Lin EN, Smits G, Vergunst H, Viddeleer AC, Geboers AD, van Berkel H, van Boven E, Kiemeney LA, Witjes F.

Clin Genitourin Cancer. 2011 Sep;9(1):14-21. doi: 10.1016/j.clgc.2011.05.004. Epub 2011 Jul 1.

PMID:
21723794
17.

Efficacy and tolerance of salvage radiotherapy after radical prostatectomy, with emphasis on high-risk patients suited for adjuvant radiotherapy.

Cremers RG, van Lin EN, Gerrits WL, van Tol-Geerdink JJ, Kiemeney LA, Vergunst H, Smans AJ, Kaanders JH, Alfred Witjes J.

Radiother Oncol. 2010 Dec;97(3):467-73. doi: 10.1016/j.radonc.2010.05.023.

PMID:
20817287
18.

Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy.

Ploeg M, Kiemeney LA, Smits GA, Vergunst H, Viddeleer AC, Geboers AD, van Berkel H, van Boven E, Aben KK, Witjes JA.

Urol Oncol. 2012 May-Jun;30(3):247-51. doi: 10.1016/j.urolonc.2009.12.020. Epub 2010 May 6.

PMID:
20451418
19.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

20.

Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy.

Yakar D, Hambrock T, Huisman H, Hulsbergen-van de Kaa CA, van Lin E, Vergunst H, Hoeks CM, van Oort IM, Witjes JA, Barentsz JO, Fütterer JJ.

Invest Radiol. 2010 Mar;45(3):121-5. doi: 10.1097/RLI.0b013e3181c7bcda.

PMID:
20065860
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk